Difficulty: Medium
Average Score: 91%
Practice
Avoidance of triggering agents is crucial in urticaria and angioedema. The MAINSTAY of pharmacologic treatment is
Correct answer
A
Rationale
In the management of urticaria and angioedema, the MAINSTAY of pharmacologic treatment is second-generation H1 antihistamines (Option A). These antihistamines are preferred due to their efficacy in blocking histamine receptors, which are responsible for the symptoms of urticaria and angioedema. They have fewer side effects like sedation compared to first-generation antihistamines, making them a safer and more effective choice.
Tricyclic antidepressants (Option B) are not typically used as a first-line treatment for urticaria and angioedema. While they may have some antihistaminic properties, their side effect profile and potential for drug interactions make them less suitable.
Corticosteroids (Option C) are reserved for severe cases or when antihistamines alone are ineffective. They are not considered the MAINSTAY of treatment due to their potential for long-term side effects and lack of specificity in targeting the underlying histamine-mediated pathway.
Leukotriene receptor blockers (Option D) are more commonly used in conditions like asthma and allergic rhinitis, where leukotrienes play a larger role. They are not the first-line treatment for urticaria and angioedema, as histamine is the primary mediator in these conditions.
In an educational context, understanding the rationale behind choosing second-generation H1 antihistamines as the MAINSTAY of treatment for urticaria and angioedema is crucial for nurses specializing in pediatric care. This knowledge helps ensure safe and effective management of these common pediatric dermatologic conditions, emphasizing the importance of evidence-based practice in providing quality care to pediatric patients.
Tricyclic antidepressants (Option B) are not typically used as a first-line treatment for urticaria and angioedema. While they may have some antihistaminic properties, their side effect profile and potential for drug interactions make them less suitable.
Corticosteroids (Option C) are reserved for severe cases or when antihistamines alone are ineffective. They are not considered the MAINSTAY of treatment due to their potential for long-term side effects and lack of specificity in targeting the underlying histamine-mediated pathway.
Leukotriene receptor blockers (Option D) are more commonly used in conditions like asthma and allergic rhinitis, where leukotrienes play a larger role. They are not the first-line treatment for urticaria and angioedema, as histamine is the primary mediator in these conditions.
In an educational context, understanding the rationale behind choosing second-generation H1 antihistamines as the MAINSTAY of treatment for urticaria and angioedema is crucial for nurses specializing in pediatric care. This knowledge helps ensure safe and effective management of these common pediatric dermatologic conditions, emphasizing the importance of evidence-based practice in providing quality care to pediatric patients.